Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Diagnostic Significance of BRCA1, RASSF1A and PTEN Methylation in Breast Lesions of Uncertain Malignant Potential

NCT07416500 is registered in ClinicalTrials.gov with Institute of Oncology Ljubljana as lead sponsor.

NCT NCT07416500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07416500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Diagnostic Significance of BRCA1, RASSF1A and PTEN Methylation in Breast Lesions of Uncertain Malignant Potential
Lead sponsor
Institute of Oncology Ljubljana
Phase
Not applicable
Overall status
Completed
Start date
September 1, 2024
Completion date
June 30, 2025
Enrollment
301 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast lesions of uncertain malignant potential (b3 lesions)